Last reviewed · How we verify

MMP with Saline infusion

Clinica Dermatologica Arbache ltda · FDA-approved active Small molecule Quality 0/100

MMP with saline infusion is a topical or injectable dermatological treatment that delivers matrix metalloproteinase enzymes in saline solution to promote skin remodeling and collagen restructuring.

MMP with Saline infusion, marketed by Clinica Dermatologica Arbache Ltda, holds a position in the dermatological market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameMMP with Saline infusion
Also known asMMP
SponsorClinica Dermatologica Arbache ltda
Drug classEnzymatic dermatological agent
TargetMatrix metalloproteinases (MMPs)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Matrix metalloproteinases (MMPs) are enzymes that break down extracellular matrix proteins, including collagen and elastin. When delivered via saline infusion in a dermatological context, MMPs facilitate controlled tissue remodeling, potentially improving skin texture, reducing scarring, and promoting wound healing or aesthetic improvement. The saline vehicle provides a stable delivery medium for the enzymatic activity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: